All In Biotech

Drug Trial Radar · NCT06238622

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

An Open-label Extension Trial of the Long-term Safety and Efficacy of BI 1015550 Taken Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) (FIBRONEER™-ON)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,666

Actual

Start

Sep 26, 2024

Primary completion

Apr 28, 2027

Study completion May 7, 2027

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need to go to the hospital, or die. Every participant takes nerandomilast as tablets for up to 1 year and 10 months. The participants may also continue their regular treatment for pulmonary fibrosis during the study. Participants visit their doctors regularly. During these visits, the doctors collect information on any health problems of the participants. Participants also regularly do lung function tests.

Conditions

  • Idiopathic Pulmonary Fibrosis
  • Progressive Pulmonary Fibrosis

Interventions

  • NerandomilastDrug

    Nerandomilast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of any adverse event over the course of the extension trial (yes/no) i.e. up until the follow-up/end of study visit planned at the latest at week 99Time frame: Up to 99 weeks and 3 days

Locations

375 sites in 44 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Arizona

    Tucson, Arizona

  • University of Southern California

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California Los Angeles

    Los Angeles, California

  • University of California Davis

    Sacramento, California

  • National Jewish Health

    Denver, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • Christiana Hospital

    Newark, Delaware

  • Georgetown University

    Washington D.C., District of Columbia

  • St. Francis Medical Institute

    Clearwater, Florida

  • University of Florida

    Gainesville, Florida

  • Clinical Research Specialists LLC - Kissimmee

    Kissimmee, Florida

  • Advanced Pulmonary Research Institute

    Loxahatchee Groves, Florida

  • Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead

    Atlanta, Georgia

  • The Emory Clinic

    Atlanta, Georgia

  • Northshore University Health System

    Evanston, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Tulane Medical Center

    New Orleans, Louisiana

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • St. Elizabeth's Medical Center

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Corewell Health William Beaumont University Hospital

    Royal Oak, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic, Rochester

    Rochester, Minnesota

  • The Lung Research Center, LLC

    Chesterfield, Missouri

  • Creighton University

    Omaha, Nebraska

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Renown Regional Medical Center

    Reno, Nevada

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

  • Northern Westchester Hospital

    Mount Kisco, New York

  • New York Presbyterian Hospital -Columbia University

    New York, New York

  • NewYork-Presbyterian/Weill Cornell Medical Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Southeastern Research Center-Winston Salem-69289

    Winston-Salem, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

Showing 40 of 375 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.